Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA
NCT ID: NCT01844635
Last Updated: 2016-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
320 participants
INTERVENTIONAL
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia
NCT01530555
Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
NCT02404025
Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
NCT01231841
Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia
NCT01997372
ATGAM General Investigation
NCT06039020
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2.5 mg/kg/day of Thymoglobulin for 5 days
2.5 mg/kg/day of Thymoglobulin for 5 days
Thymoglobulin
3.5 mg/kg/day of Thymoglobulin for 5 days
3.5 mg/kg/day of Thymoglobulin for 5 days
Thymoglobulin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thymoglobulin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: younger than 70 years old
* Severity: SAA, VSAA.
* Interval between diagnosis and registration \<6 months.
* Written informed consent from the caretakers and/or whenever possible consent from the patient.
Exclusion Criteria
69 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nagoya University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hideki Muramatsu
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seiji Kojima, MD., PhD.
Role: PRINCIPAL_INVESTIGATOR
Department of Pediatrics, Nagoya University Graduate School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pediatrics, Nagoya University Graduate School of Medicine
Nagoya, Aichi-ken, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APBMT AAWG-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.